- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05335850
Yoga for Mental Health in Parkinson's Patients
Meditation and Breathing for Mental Health in Parkinson's Disease Patient
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mental health issues caused by emotional and behavioral changes are common among people diagnosed with Parkinson's disease. Research from the Parkinson's Foundation's Parkinson's Outcomes Project has found that anxiety and depression play a key role in the disease's impact on people's quality of life. The death of dopamine-producing cells in the brain affects both movement and mood. As a result, both anxiety and depression are common non-motor symptoms of the disease rather than reactions to the diagnosis.
According to the Parkinson's Outcomes Project, during their illness:
- At least 50% of people will experience some form of depression
- At least 40% of people will experience an anxiety disorder
Forms of anxiety include Generalized Anxiety Disorder, Anxiety Attacks, Social Avoidance, and OCD1. Depression in Parkinson's disease often manifests as dissatisfaction with life, sadness, irritability, pessimism, and suicidal thoughts.
Meditative techniques have been shown to effectively reduce symptoms of anxiety and depression. Treating these non-motor symptoms can have a positive impact on people with Parkinson's disease by decreasing disability and improving their quality of life.
The purpose of this study is to investigate the impact of a set of simple, safe and scalable, digitally delivered meditation and breathing practices on the neuropsychological and movement disorder symptoms in patients with Parkinson's Disease over a period of 18-20 weeks. The intervention consists of a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga). Our recent studies using similar interventions have shown feasibility and acceptance as well as Improved perceived stress in healthy subjects.
The subjects will be randomized into two groups after they agree to participate in the study, an intervention group (Group 1) and a waitlisted control group (Group 2). Both groups will learn and practice the intervention for 12 weeks total.The intervention is made of a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga). Both groups will also take study surveys at 4 timepoints which are each 6 weeks apart (Baseline, T2, T3, and T4). The study surveys consist of an online survey and a clinician, phone administered survey.
This trial will be conducted in 2 phases:
Phase 1: If participants are in the intervention group, they will be asked to learn the practices first for 6 weeks, from T1-T2. They will be asked to complete weekly activity logs for these 6 weeks and the study survey at T2 (6 weeks after learning the intervention). Participants in the waitlisted control group will be asked to perform their regular daily routine as they wait to be enrolled into the intervention at T2 (6 weeks after Baseline). The waitlisted control group will also complete the study survey at T2.
Phase 2: After T2, the intervention group is no longer asked to attend weekly review webinars but they will continue to do weekly activity logs for 6 weeks until until T3. They will then complete the study survey at T3. After T3, they will not be sent any activity logs for the next 6 weeks until T4. At T4, they will be asked to complete the study survey and satisfaction survey. The waitlisted control group will begin the intervention at T2 and will attend review webinars for 6 weeks until T3 at which they will complete the study survey. After T3, they are no longer asked to attend weekly webinars but they will continue to do weekly activity logs for 6 weeks until until T4. At T4, they will be asked to complete the study survey and satisfaction survey.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Beth Israel Deaconess Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age above 18
- Interested in attending the Breath, Sound, and Meditation Webinar
- Diagnosed with Parkinson's Disease
- PAS score of 12 or higher
- Able to read and comprehend English.
- Physically and mentally able to participate in the study procedure
- Currently residing in the United States.
Exclusion Criteria:
- Severe stage of PD
- Any medically limiting diagnosis that prevents a patient from doing the intervention or completing the assessments as determined by the PI such as severe Major Depression (under medication), Schizophrenia, Bipolar disorder.
- Not able to self-consent to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
Breathing and Wellness Webinar: a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
|
Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
|
|
Active Comparator: Waitlisted Control Group
This group will be asked to wait for 6 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
|
Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm. Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Compliance
Time Frame: For Phase 1 analysis: Baseline to week 6. For Phase 2 analysis: Baseline to week 18.
|
The weekly compliance questionnaire is a tool which helps the participants to keep track of their activities each week.
This enables the study team to measure compliance and protocol adherence by the participants by collecting information on their routine activity practiced and its frequency.
This will be reported in "Number of days an intervention was practiced in a week".
Participants completing at least 4 days of activity would be considered as compliant for that week.
|
For Phase 1 analysis: Baseline to week 6. For Phase 2 analysis: Baseline to week 18.
|
|
Change in Anxiety
Time Frame: For Phase 1 analysis: Baseline to week 12. For Phase 2 analysis: Baseline to week 18.
|
Parkinson's Anxiety Scale (PAS) is a 12-item validated observer or patient-rated scale consisting of three subscales for persistent anxiety, episodic anxiety, and avoidance behavior in patients with Parkinson Disease.
Participants are asked to rate on a scale of 0 (not or never) and 4 (severe or almost always).
|
For Phase 1 analysis: Baseline to week 12. For Phase 2 analysis: Baseline to week 18.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Perceived Stress Scale (PSS)
Time Frame: For Phase 1 analysis: Baseline to 6 weeks. For Phase 2 analysis: Baseline to 18 weeks.
|
PSS is a 10-question validated instrument that assesses stress.
Participants are asked to rate on a scale of 0 (never) to 4 (very often) how often they agree with various statements.
|
For Phase 1 analysis: Baseline to 6 weeks. For Phase 2 analysis: Baseline to 18 weeks.
|
|
Change in GRID-Hamilton Depression Scale (HAMD)
Time Frame: For Phase 1 analysis: Baseline to 6 weeks. For Phase 2 analysis: Baseline to 18 weeks.
|
The GRID-HAMD-17 is used to measure the frequency and intensity of depressive symptoms.
Participants are asked to rate frequency of each statement on a scale from "Absent or clinically insignificant" to "Almost all the time."
Rating for intensity is on a scale from Absent to Very Severe.
|
For Phase 1 analysis: Baseline to 6 weeks. For Phase 2 analysis: Baseline to 18 weeks.
|
|
Change in MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time Frame: For Phase 1 analysis: Baseline to week 12. For Phase 2 analysis: Baseline to week 18.
|
This is a four-part survey designed for patients with Parkinson Disease.
Part I covers non-motor experiences of daily living, Part II covers motor experiences of daily living, Part III covers motor examination and Part IV covers motor complications.
|
For Phase 1 analysis: Baseline to week 12. For Phase 2 analysis: Baseline to week 18.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Balachundar Subramaniam, MD, MPH, Beth Israel Deaconess Medical Center
Publications and helpful links
General Publications
- Rangasamy V, Thampi Susheela A, Mueller A, F H Chang T, Sadhasivam S, Subramaniam B. The effect of a one-time 15-minute guided meditation (Isha Kriya) on stress and mood disturbances among operating room professionals: a prospective interventional pilot study. F1000Res. 2019 Mar 26;8:335. doi: 10.12688/f1000research.18446.1. eCollection 2019.
- Rain M, Subramaniam B, Avti P, Mahajan P, Anand A. Can Yogic Breathing Techniques Like Simha Kriya and Isha Kriya Regulate COVID-19-Related Stress? Front Psychol. 2021 Apr 15;12:635816. doi: 10.3389/fpsyg.2021.635816. eCollection 2021.
- Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil Diaz MC, Richard IH. Change in the Parkinson Anxiety Scale correlates with change in other clinical measures of anxiety over time. Clin Park Relat Disord. 2021 Dec 13;6:100126. doi: 10.1016/j.prdoa.2021.100126. eCollection 2022.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022P000212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on Isha Kriya
-
Beth Israel Deaconess Medical CenterCompletedBurnout, Professional | Occupational Stress | Affective SymptomsUnited States
-
Beth Israel Deaconess Medical CenterNot yet recruitingRelationship, Family | Well-Being, PsychologicalUnited States
-
Beth Israel Deaconess Medical CenterCompletedKnee Osteoarthritis | Osteo Arthritis Knee | Knee Injuries | Osteonecrosis | Opioid Use Disorder | Opioid Dependence | Arthropathy of Knee | Opioid Use | Meditation | Knee DiseaseUnited States
-
Prof. Ivan BautmansUniversity Hospital, Antwerp; Universiteit Antwerpen; INNOVIRIS; AAL; Leiehome vzwNot yet recruiting
-
Beth Israel Deaconess Medical CenterCompleted
-
Lawson Health Research InstituteWithdrawn
-
Beth Israel Deaconess Medical CenterCompleted
-
Mount Sinai Hospital, CanadaNova Scotia Health Authority; St. Joseph's Health Care London; Atlas Institute... and other collaboratorsRecruitingPTSD | Quality of Life | Pain | Anxiety | Depressive Symptoms | Post Traumatic Stress DisorderCanada
-
The University of QueenslandCompletedPosttraumatic Stress Disorder
-
Beth Israel Deaconess Medical CenterCompletedCovid19 | Stress | Anxiety DepressionUnited States